Dermapharm H1 FY26 adjusted EBITDA jumps 10.3% to EUR 163.2 million; revenue rises 2.9% to EUR 591 million

• Dermapharm H1 2026 revenue rose 2.9% to EUR 591 million; adjusted EBITDA climbed 10.3% to EUR 163.2 million.
• Adjusted EBITDA margin widened 1.8 percentage points to 27.6%; IFRS EBITDA increased 27.3% to EUR 184.5 million.
• Branded pharmaceuticals revenue grew 11.6% to EUR 321.9 million, driven by organic growth and first-time consolidation of Mucos Group and F. Trenka.
• Parallel import revenue fell 14% to EUR 91.6 million on portfolio restructuring; IFRS EBITDA improved to EUR -0.2 million.
• 2026 outlook reaffirmed: revenue EUR 1.18-1.22 billion; adjusted EBITDA EUR 331-341 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermapharm Holding SE published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2387614_en) on August 25, 2026, and is solely responsible for the information contained therein.